News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Top Five Trends in Life Sciences Compliance for 2022

January 7, 2022
By Company Press Release
Article

Patient protection and social influence among trends to look out for as calendar turns.

Trend 1: Goodbye Doctors, Hello Patients – John Oroho, Executive Vice President and Chief Strategy Officer of Porzio Life Sciences, LLC

Pharmaceutical companies will continue to shift their marketing efforts—and dollars—from healthcare providers to patients. The regulatory structure now in place seeks to protect patients by regulating interactions between drug manufacturers and physicians. As those regulations become more restrictive, manufacturers are increasingly seeking out ways to bypass physicians and connect directly with patients.

Trend 2: Here Come the Influencers – John Oroho, Executive Vice President and Chief Strategy Officer of Porzio Life Sciences, LLC

Social media influencers will continue to become a more significant element of pharmaceutical marketing campaigns. In 2020, the small biotech company Biohaven made Khloe Kardashian a paid spokesperson for its migraine medication, Nurtec ODT. In addition to making appearances on television shows like The View, Kardashian promoted the drug on her social media channels with more than 100 million followers. Weeks later, AbbVie announced Serena Williams as a spokesperson for its competing migraine drug. Williams, too, posted sponsored content on her Instagram.

Trend 3: Regulators Look Abroad – Michelle Axelrod, Senior Vice President of Porzio Life Sciences, LLC

Increasingly, countries are beginning to borrow ideas on transparency regulation from each other. Many countries outside the US have more aggressive reporting criteria on spend transparency, and we can expect some of those requirements to make their way into U.S. law. Senators Chuck Grassley (R-IA) and Ron Wyden (D-OR), for instance, have recommended that pharmaceutical companies be required to report payments made to tax-exempt patient advocacy groups. Likewise, it would not be surprising if the US adopted French rules that require reporting on payments to social media influencers.

Trend 4: Price Transparency Is the New Black – Jennifer A. Romanski, Senior Vice President of Porzio Life Sciences, LLC

Price transparency regulation will continue to proliferate. Transparency regulations in the United States originated with rules on spend transparency, which were enacted with the intent of decreasing drug prices. Rules requiring transparency on, for instance, the amount spent on meals for physicians, did not result in lower prices. Governments have moved on to price transparency regulations as their next most promising avenue to affect drug prices. There are currently 18 states with price transparency regulations in place, and 17 with proposed legislation. It would be a surprise if both numbers did not increase in 2022.

Trend 5: Unintended Consequences Revealed – Michael O’Connor, Senior Vice President and Chief Product Officer of Porzio Life Sciences, LLC

The unintended consequences of price transparency laws should begin to show themselves in 2022. Price transparency regulations in at least 7 states require pharmaceutical companies to reveal information about their marketing activities. That is just one piece of information that pharmaceutical companies have been reluctant to report publicly, for fear of handing valuable business intelligence to their competitors. In 2022, we should begin to see whether that provision or others begin to have any unintended consequences on market behavior.

Recent Videos
Related Content

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Don Tracy, Associate Editor
May 19th 2025
Article

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.


Cell and Gene Therapy Check-in 2024

Cell and Gene Therapy Check-in 2024

Miranda Schmalfuhs
January 18th 2024
Podcast

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.


Earned Media and ASCO: Provide Context Beyond the Data

Earned Media and ASCO: Provide Context Beyond the Data

Michael Christel
May 13th 2025
Article

The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.


Industry Outlook 2022

Industry Outlook 2022

Elaine Quilici;Miranda Schmalfuhs
January 20th 2022
Podcast

Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers.


Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D

Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D

Don Tracy, Associate Editor
April 28th 2025
Article

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.


Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation

Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation

Don Tracy, Associate Editor
April 22nd 2025
Article

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics production, gene therapy capabilities, and next generation R&D centers.

Related Content

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Don Tracy, Associate Editor
May 19th 2025
Article

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.


Cell and Gene Therapy Check-in 2024

Cell and Gene Therapy Check-in 2024

Miranda Schmalfuhs
January 18th 2024
Podcast

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.


Earned Media and ASCO: Provide Context Beyond the Data

Earned Media and ASCO: Provide Context Beyond the Data

Michael Christel
May 13th 2025
Article

The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.


Industry Outlook 2022

Industry Outlook 2022

Elaine Quilici;Miranda Schmalfuhs
January 20th 2022
Podcast

Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers.


Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D

Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D

Don Tracy, Associate Editor
April 28th 2025
Article

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.


Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation

Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation

Don Tracy, Associate Editor
April 22nd 2025
Article

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics production, gene therapy capabilities, and next generation R&D centers.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.